ATM and cancer: Numerous, promising preclinical and clinical studies suggest that ATM, ATR, CHK1, CHK2 and WEE1 inhibitors or modulators, alone or in combination with other therapeutics, could be potent therapeutic options for certain cancers, including TNBC [24,25,26,27,28].